Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 4, 2002, Pages 291-298

  Papadopoulou, M ^a,b   Ji, M ^a,b   Ji, X ^a,b   Bloomer, W ^a,b  

^a Radiation Medicine Institute   (United States)

^b EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

5 Fluorouracil; Hypoxic cytotoxins; NLCQ 1; Potentiation; Tirapazamine

Indexed keywords

4 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; CYTOTOXIN; FLUOROURACIL; NLCQ 1; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANOXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; DRUG SYNERGISM; FEMALE; FLUOROURACIL; IMIDAZOLES; MICE; MICE, INBRED BALB C; QUINOLINES; TRIAZINES; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0036387403     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0491-x     Document Type: Article

References (56)

1. Aboagye EO, Maxwell RJ, Kelson AB, Tracy M, Lewis AD, Graham MA, Horsman MR, Griffiths JR, Workman P (1997) Preclinical evaluation of fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for measurement of tumor hypoxia. Cancer Res 57:3314
2. Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Coates S, Simmons T, Neefe J, von Roemeling R (1997) Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann Oncol 8:363
3. Blumenthal RD, Taylor A, Osorio L, Ochakovskaya R, Raleigh J, Papadopoulou M, Bloomer WD, Goldenberg DM (2001) Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int J Cancer 94:564
4. Bremner JCM, Stratford IJ, Bowler J, Adams GE (1990) Bioreductive drugs and the selective induction of tumor hypoxia. Br J Cancer 61:717
5. Brown MJ (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163
6. Brown MJ, Lemmon MJ (1990) Potentiation by the hypoxic cytotoxin SR4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50:7745
7. Cuvier C, Jang A, Hill RP (1997) Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clin Exp Metastasis 15:19
8. Dorie MJ, Brown JM (1993) Tumor-specific, schedule-dependent interaction between tirapazamine (SR4233) and cisplatin. Cancer Res 53:4633
9. Dorie MJ, Brown JM (1997) Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 39:361
10. Durand RE, Olive PL (1997) Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Investig 5:213
11. Friery OP, Gallagher R, Murray MM, Hughes CM, Galligan ES, McIntyre IA, Patterson LH, Hirst DG, McKeown SR (2000) Enhancement of the anti-tumor effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br J Cancer 82:1469
12. Gallagher R, Hughes CM, Murray MM, Friery OP, Patterson LH, Hirst DG, McKeown SR (2001) The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer 85:625
13. Graham CH, Forsdike J, Fitzgerald CJ, MacDonald-Goodfellow S (1999) Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 80:617
14. Grau C, Overgaard J (1988) Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 13:301
15. Hay MP, Wilson WR, Moselen JW, Palmer BD, Denny WA (1994) Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. J Med Chem 37:381
16. Hicks KO, Fleming Y, Siim BG, Koch CJ, Wilson WR (1998) Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys 42:641
17. Hirst DG, Brown JM, Hazlehurst JL (1983) Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res 43:1961
18. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of uterine cervix. Cancer Res 56:4509
19. Holden SA, Teicher BA, Ara G, Herman TS, Coleman CN (1992) Enhancement of alkylating agent activity by SR-4233 in FSaIIC murine fibrosarcoma. J Natl Cancer Inst 84:187
20. Kennedy KA (1987) Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des 2:181
21. Kovacs MS, Hocking DJ, Evans JW, Siim BG, Wouters BG, Brown JM (1999) Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer 80:1245
22. Lartigau E, Guichard M (1996) The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumors. Br J Cancer 73:1480
23. Marshall JL, Figueira M, Dahut W, Rizvi N, von Roemeling R (1998) Tirapazamine plus cisplatin in the treatment of patients with breast cancer and other platinum resistant tumors. A phase II clinical trial. Cancer Ther 1:237
24. Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R, Kris MG (1997) Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small cell lung cancer. Ann Oncol 8:1269
25. Papadopoulou MV, Miller A, Seskey T, Epperly MW, Bloomer WD (1993) Potentiation of antineoplastic drugs in vitro and in vivo by intercalating bioreductive agents. Radiat Oncol Investig 1:206
26. Papadopoulou MV, Ji M, Bloomer WD (1996) THNLA-1: a DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo. In Vivo 10:49
27. Papadopoulou MV, Ji M, Bloomer WD (1996) THNLA-1 as radio/chemosensitizer of EMT6 tumors in mice. Br J Cancer 74 [Suppl XXVII]: S267
28. Papadopoulou MV, Ji M, Rao MK, Bloomer WD (1997) 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. I. Oncol Res 9:249
29. Papadopoulou MV, Ji M, Rao MK, Bloomer WD (1997) 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound; cytotoxicity and reduction studies. Second International Conference on Redox Processes and Cancer: Molecular Biology and Therapeutics. Banff, Alberta, Canada, 7-10 April. Proceedings
30. Papadopoulou MV, Ji M, Bloomer WD (1998) NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int J Radiat Oncol Biol Phys 42:775
31. Papadopoulou MV, Ji X, Xue C, Bloomer WD (2000) In vitro schedule-dependent potentiation of taxol, 5FU and cisDDP by the hypoxic cytotoxin NLCQ-1. Comparison with tirapazamine. 11th International Conference on Chemical Modifiers of Cancer Treatment. Tumor Physiology and Cancer Treatment. Banff, Alberta, Canada, 5-7 October. Proceedings
32. Papadopoulou MV, Ji M, Rao MK, Bloomer WD (2000) 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res 12:185
33. Papadopoulou MV, Ji M, Rao MK, Bloomer WD (2000) 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1). A novel bioreductive agent as radiosensitizer in vitro and in vivo. Comparison with tirapazamine. Oncol Res 12:325
34. Papadopoulou MV, Ji M, Bloomer WD (2000) Potentiation of chemotherapeutic drugs by the bioreductive compound NLCQ-1 against SCCVII tumors in mice. Proc Am Assoc Cancer Res 41:766
35. Papadopoulou MV, Ji M, Bloomer WD (2001) Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother Pharmacol 48:160
36. Papadopoulou MV, Ji X, Bloomer WD (2001) Mechanisms involved in the potentiation of taxol or 5-FU by the hypoxic cytotoxin NLCQ-1. Clinical Cancer Res [Suppl] 7:3679s
37. Papadopoulou MV, Ji X, Bloomer WD (2002) Hypoxia-dependent retinal toxicity of NLCQ-1 and tirapazamine in BALB/c mice. Proc Am Assoc Cancer Res 43:1092
38. Papadopoulou MV, Ji M, Bloomer WD, Hollingshead MG (2002) Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts. J Exp Ther Oncol 2:(in press)
39. Patterson LH, McKeown SR (2000) AQ4N: a new approach to hypoxia-activated cancer chemotherapy (review). Br J Cancer 83:1589
40. Peters KB, Wang H, Brown MJ, Iliakis G (2001) Inhibition of DNA replication by tirapazamine. Cancer Res 61:5425
41. Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC (1997) Human tumor xenograft models in NCI drug development. In: Teicher B (ed) Anticancer drug development guide: preclinical screening, clinical trials, and approval. Humana Press, Totowa, pp 101-125
42. Rice GC, Hoy C, Schimke RT (1986) Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci U S A 83:5978
43. Rockwell SC, Kallman RF, Fajardo LF (1972) Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst 49:735
44. Sartorelli AC (1988) Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res 48:775
45. Schmoll HJ, Buchele T, Grothey A, Dempke W (1999) Where do we stand with 5-fluorouracil? (review). Semin Oncol 26:589
46. Siemann DW, Allalunis-Turner MJ (1988) Potentiation of combination chemotherapy by nitroheterocyclics. Int J Radiat Oncol Biol Phys 16:973
47. Siemann DW, Hinchman CA (1998) Potentiation of cisplatin activity by the bioreductive agent tirapazamine. Radiother Oncol 47:215
48. Siemann DW, Mulcahy RT (1986) Sensitization of cancer chemotherapeutic agents by nitroheterocyclics. Biochem Pharmacol 35:111
49. Siemann DW, Sutherland RM (1992) Potentiation of alkylating chemotherapy by dual function nitrofurans in multicell spheroids and solid tumors. Radiother Oncol 24:239
50. Teicher BA, Holden SA, al-Achi A, Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaII murine fibrosarcoma. Cancer Res 50:3339
51. Thomas DM, Zalcberg JR (1998) 5-Fluorouracil: a pharmacological paradigm in the use of cytotoxics (review). Clin Exp Pharmacol Physiol 25:887
52. Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, Rodriquez R, Drobins P, Miller W Jr, Meehan L, McKeon A, Devin J, von Roemeling R, Viallet J (1998) Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 16:3524
53. Vincent M, Labianca R, Harper P (1999) Which 5-fluorouracil regimen? - the great debate (review). Anticancer Drugs 10:337
54. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J (2000) Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. J Clin Oncol 18:1351
55. Zaider M (1990) Concepts for describing the interaction of two agents. Radiat Res 123:257
56. Zhivotovsky B, Joseph B, Orrenius S (1999) Tumor radiosensitivity and apoptosis. Exp Cell Res 248:10